3D Systems faces class action lawsuit over securities violations.
PorAinvest
domingo, 17 de agosto de 2025, 9:36 am ET2 min de lectura
DDD--
The class action, filed in the United States District Court for the District of Delaware, docketed under 25-cv-00734, is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired 3D Systems securities during the Class Period. Investors have until August 12, 2025, to ask the Court to appoint them as Lead Plaintiff for the class [2].
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
1. 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions.
2. The updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.
3. As a result, the Company’s public statements were materially false and misleading at all relevant times [2].
3D Systems provides 3D printing and digital manufacturing solutions globally. The Company earns revenue from the sale of products and services through its Healthcare Solutions and Industrial Solutions segments. The Healthcare Solutions segment includes dental, medical devices, personalized health services, and the Regenerative Medicine Program [2].
The Regenerative Medicine Program focuses on the use of additive manufacturing for human organ transplantation. Since 2018, 3D Systems has partnered with United Therapeutics Corporation with a long-term goal of developing the capability to 3D print lungs for patients with end-stage lung disease. The terms of this partnership, known as the United Partnership, include specific milestone criteria that must be met for a stage in the development process to be considered completed [2].
In March 2025, 3D Systems released its full-year 2025 guidance, projecting revenue within the range of $420 million to $435 million, representing essentially flat to modest growth. The Company also projected non-GAAP Gross Profit Margin within the range of 37% to 39% and non-GAAP Operating Expense within the range of $200 million to $220 million [2].
The complaint alleges that Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
1. 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions.
2. The updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.
3. As a result, the Company’s public statements were materially false and misleading at all relevant times [2].
Investors who purchased or otherwise acquired 3D Systems securities during the Class Period are encouraged to review the Complaint and consider joining the class action. To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980 [2].
References:
[1] https://www.globenewswire.com/news-release/2025/08/12/3132085/9788/en/DDD-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-3D-Systems-Corporation-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html
[2] https://www.morningstar.com/news/globe-newswire/9509973/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-3d-systems-corporation-and-certain-officers-ddd
Pomerantz LLP has filed a class action lawsuit against 3D Systems Corporation and certain officers on behalf of investors who purchased 3D Systems securities between August 13, 2024 and May 12, 2025. The lawsuit alleges violations of federal securities laws and seeks damages and remedies under the Securities Exchange Act of 1934. Investors have until August 12, 2025 to ask the Court to appoint them as lead plaintiff.
Pomerantz LLP has filed a class action lawsuit against 3D Systems Corporation (NYSE: DDD) and certain officers on behalf of investors who purchased 3D Systems securities between August 13, 2024, and May 12, 2025. The lawsuit alleges violations of federal securities laws and seeks damages and remedies under the Securities Exchange Act of 1934 [2].The class action, filed in the United States District Court for the District of Delaware, docketed under 25-cv-00734, is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired 3D Systems securities during the Class Period. Investors have until August 12, 2025, to ask the Court to appoint them as Lead Plaintiff for the class [2].
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
1. 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions.
2. The updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.
3. As a result, the Company’s public statements were materially false and misleading at all relevant times [2].
3D Systems provides 3D printing and digital manufacturing solutions globally. The Company earns revenue from the sale of products and services through its Healthcare Solutions and Industrial Solutions segments. The Healthcare Solutions segment includes dental, medical devices, personalized health services, and the Regenerative Medicine Program [2].
The Regenerative Medicine Program focuses on the use of additive manufacturing for human organ transplantation. Since 2018, 3D Systems has partnered with United Therapeutics Corporation with a long-term goal of developing the capability to 3D print lungs for patients with end-stage lung disease. The terms of this partnership, known as the United Partnership, include specific milestone criteria that must be met for a stage in the development process to be considered completed [2].
In March 2025, 3D Systems released its full-year 2025 guidance, projecting revenue within the range of $420 million to $435 million, representing essentially flat to modest growth. The Company also projected non-GAAP Gross Profit Margin within the range of 37% to 39% and non-GAAP Operating Expense within the range of $200 million to $220 million [2].
The complaint alleges that Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:
1. 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions.
2. The updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.
3. As a result, the Company’s public statements were materially false and misleading at all relevant times [2].
Investors who purchased or otherwise acquired 3D Systems securities during the Class Period are encouraged to review the Complaint and consider joining the class action. To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980 [2].
References:
[1] https://www.globenewswire.com/news-release/2025/08/12/3132085/9788/en/DDD-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-3D-Systems-Corporation-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html
[2] https://www.morningstar.com/news/globe-newswire/9509973/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-3d-systems-corporation-and-certain-officers-ddd
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios